Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR13311157

—

f31a5a4e-f06e-5fb2-abc8-0b642c36cbf8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.540
  • MTORC1_SIGNALING+0.540
  • G2M_CHECKPOINT+0.530
  • UNFOLDED_PROTEIN_RESPONSE+0.520
  • MYC_TARGETS_V1+0.500
  • HYPOXIA+0.460
  • MYC_TARGETS_V2+0.440
  • GLYCOLYSIS+0.430
  • PROTEIN_SECRETION+0.420
  • TNFA_SIGNALING_VIA_NFKB+0.390

Top 10 suppressed

  • PANCREAS_BETA_CELLS-0.200
  • BILE_ACID_METABOLISM-0.090
  • SPERMATOGENESIS-0.090
  • HEME_METABOLISM-0.030
  • KRAS_SIGNALING_DN-0.030
  • FATTY_ACID_METABOLISM+0.000
  • MYOGENESIS+0.020
  • ALLOGRAFT_REJECTION+0.060
  • XENOBIOTIC_METABOLISM+0.070
  • PEROXISOME+0.080

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-85-8666-01A-11R-2403-07
lung-landscapes@6
—cohortSQ10.937
2SRR934867
brain-umap@2
——0.928
3E317AD4C-E877-499A-B108-2F39A40D1682
brain-umap@2
——0.920
4633064DB-D3ED-4B5F-B48F-6924AD719647
brain-umap@2
——0.917
5TCGA-51-4079-01A-01R-1100-07
lung-landscapes@6
—cohortSQ20.915
655E3F1FB-D55D-42F8-A9E1-7828F7BFF595
brain-umap@2
——0.912
766FF1C46-83F0-4EEC-9871-448C8C7EA3AE
brain-umap@2
——0.906
8443B59BB-0BFD-459A-896E-FA07AA6C3A45
brain-umap@2
——0.902
9R275
bladder-landscape@3
——0.901
1046061E4B-5256-42AD-BA9A-FBCEBE92B09A
brain-umap@2
——0.900

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 44 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.540Inavolisib— uncovered
MTORC1_SIGNALING0.540Inavolisib— uncovered
G2M_CHECKPOINT0.530Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.520Idelalisib— uncovered
MYC_TARGETS_V10.500Inavolisib— uncovered
HYPOXIA0.460Idelalisib— uncovered
MYC_TARGETS_V20.440Idelalisib— uncovered
GLYCOLYSIS0.430Inavolisib— uncovered
PROTEIN_SECRETION0.420Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.390Inavolisib— uncovered
APICAL_SURFACE0.380Temsirolimus— uncovered
CHOLESTEROL_HOMEOSTASIS0.380Remibrutinib— uncovered
ANDROGEN_RESPONSE0.360Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.360Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.360Inavolisib— uncovered
HEDGEHOG_SIGNALING0.350Inavolisib— uncovered
ANGIOGENESIS0.340Remibrutinib— uncovered
MITOTIC_SPINDLE0.340Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.340Remibrutinib— uncovered
INTERFERON_GAMMA_RESPONSE0.330Idelalisib— uncovered